Delayed
Nasdaq
10:01:41 2024-04-30 am EDT
|
5-day change
|
1st Jan Change
|
1.205
USD
|
+1.26%
|
|
-0.41%
|
-11.40%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
636.2
|
577.8
|
168.1
|
31.21
|
60.62
|
53.38
|
-
|
-
|
Enterprise Value (EV)
1 |
449.2
|
318.1
|
-6.56
|
-45.36
|
60.62
|
53.38
|
53.38
|
53.38
|
P/E ratio
|
-7.57
x
|
-4.21
x
|
-1.38
x
|
-0.29
x
|
5.04
x
|
-1.82
x
|
-2.7
x
|
-59.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-8.49
x
|
-4.85
x
|
-1.43
x
|
-0.3
x
|
-0.85
x
|
-0.69
x
|
-0.53
x
|
-
|
EV / FCF
|
-9,186,608
x
|
-5,779,416
x
|
-1,631,542
x
|
-320,148
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
3.43
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
31,605
|
41,451
|
43,652
|
43,774
|
44,574
|
44,861
|
-
|
-
|
Reference price
2 |
20.13
|
13.94
|
3.850
|
0.7129
|
1.360
|
1.190
|
1.190
|
1.190
|
Announcement Date
|
3/16/20
|
3/18/21
|
3/17/22
|
3/23/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-74.96
|
-119
|
-117.4
|
-104
|
-71.05
|
-77.6
|
-100.6
|
-
|
EBIT
1 |
-75.81
|
-120.2
|
-118.8
|
-105.4
|
-71.67
|
-77
|
-47.7
|
-1.9
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-72.96
|
-119.7
|
-119.1
|
-105.9
|
12.53
|
-77
|
-46.7
|
-0.9
|
Net income
1 |
-72.96
|
-119.7
|
-119.1
|
-105.9
|
12.16
|
-77
|
-46.7
|
-0.9
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-2.660
|
-3.310
|
-2.780
|
-2.420
|
0.2700
|
-0.6533
|
-0.4400
|
-0.0200
|
Free Cash Flow
|
-69.25
|
-99.98
|
-103
|
-97.48
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/16/20
|
3/18/21
|
3/17/22
|
3/23/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-32.62
|
-27.96
|
-29.42
|
-27.77
|
-22.98
|
-25.26
|
-25.22
|
-15.73
|
-21.09
|
-9.627
|
-16
|
-16
|
-20
|
-25
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-32.61
|
-28.23
|
-29.83
|
-28.05
|
-22.97
|
-25.03
|
-24.96
|
67.48
|
-21.58
|
-8.408
|
-16
|
-16
|
-20
|
-25
|
-
|
Net income
1 |
-32.61
|
-28.23
|
-29.83
|
-28.05
|
-22.97
|
-25.03
|
-24.96
|
67.48
|
-21.58
|
-8.785
|
-16
|
-16
|
-20
|
-25
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.7500
|
-0.6500
|
-0.6800
|
-0.6400
|
-0.5200
|
-0.5700
|
-0.5700
|
1.520
|
-0.4800
|
-0.2000
|
-0.3600
|
-0.0800
|
-0.1000
|
-0.1300
|
-0.1200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/4/21
|
3/17/22
|
5/10/22
|
8/9/22
|
11/8/22
|
3/23/23
|
5/11/23
|
8/10/23
|
11/9/23
|
3/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
187
|
260
|
175
|
76.6
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-69.3
|
-100
|
-103
|
-97.5
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-47.4%
|
-54.4%
|
-56.2%
|
-86.5%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-43.7%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
167
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
5.870
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
1.59
|
1.18
|
2.46
|
0.27
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/16/20
|
3/18/21
|
3/17/22
|
3/23/23
|
3/14/24
|
-
|
-
|
-
|
Last Close Price
1.19
USD Average target price
2
USD Spread / Average Target +68.07% Consensus |
1st Jan change
|
Capi.
|
---|
| -11.40% | 53.38M | | -2.98% | 102B | | +1.68% | 96.29B | | +2.10% | 22.18B | | -15.28% | 21.2B | | -8.93% | 18.31B | | -39.98% | 17.38B | | -14.32% | 16.36B | | +5.59% | 13.97B | | +32.25% | 12.17B |
Bio Therapeutic Drugs
|